Nordic and BeeKeeperAI Partner | To Accelerate AI-driven Clinical Decision Support at the Point of Care

Nordic, a global health and technology consulting company, and BeeKeeperAI®, Inc. a pioneer in privacy-enhancing, multi-party collaboration software for real-world AI development and deployment, announced today a strategic partnership to bring to market a new real-world, end-to-end RightAI™ solution that is aimed at connecting biopharmaceutical and medical technology companies, healthcare delivery organizations, and physicians in the development, validation, and deployment of AI and machine learning-based CDSS tools that support clinical workflows within electronic health record (EHR) systems.

The partnership intends for RightAI to assist physicians with optimizing patient outcomes through the use of native CDSS tools within the EHR and support efforts to identify patients who are optimal candidates for clinical trials.

Precise decision-making at the point of care can be difficult given a variety of factors, such as a patient’s unique clinical characteristics, chronic conditions, and the complexities of biological and disease factors. The development of a new standard of care resulting from the collaboration between biopharmaceutical and medical technology companies and healthcare systems can enable new personalized care programs, provide novel therapies, and meet patients’ goals for better health. RightAI seeks to offer solutions that enable clinicians to identify these optimal treatment plans for the right patient at the right time. Leveraging the power of data at the point of care from this collaboration can transform care delivery.

“By embracing AI in healthcare, we are transforming how care is delivered and setting a new standard for patient-centered, personalized, and efficient care,” said Nordic Chief Medical Officer Craig Joseph, MD. “Our partnership with BeeKeeperAI and the integration of RightAI into the EHR allows us to introduce AI models that create real-world impact and drive better patient outcomes.”

Along with the potential both to unlock data insights and enable more precise therapeutic decisions by clinicians, RightAI also intends to accelerate time-to-market for AI developers building CDSSs and other machine learning solutions for healthcare. Biopharmaceutical and medical technology companies offering therapies for complex diseases can leverage RightAI to assist with the development of CDSSs based on real-world data and quickly achieve real-world impacts.

“Together with Nordic, BeeKeeperAI’s privacy enhancing platform can address the last mile of AI/machine learning-based CDSS: real-world deployment and ongoing monitoring for performance drift. The ability to develop and deploy solutions in real-world settings enhances and accelerates the impact of CDSS,” said Michael Blum, MD, co-founder and chief executive officer at BeeKeeperAI. “Instead of taking years to achieve impact, RightAI will enable CDSS to impact patient outcomes in a matter of months from the start of development to impact. This acceleration will enable life-changing therapies to reach patients more quickly, fulfilling the promise of healthcare AI.”

Dr. Joseph added, “Following the guiding principles of clinical decision support, RightAI brings the right information to the right provider in the right format through the right channels at the right time to help clinicians improve the precision of their treatment decisions for their patients.”

The partnership continues Nordic and BeeKeeperAI’s leadership in the healthcare AI space. Nordic is a comprehensive delivery partner of BeeKeeperAI’s EscrowAI™, a privacy-enhancing collaboration platform for trustworthy and responsible AI that enables data controllers to maintain control and protect the privacy of their real-world patient data and developers to responsibly develop and deploy AI into the EHR and clinical workflows.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”